Recurrent primary biliary cirrhosis after liver transplantation.
Recurrent primary biliary cirrhosis (PBC) is an important clinical outcome after liver transplantation (LT) in selected patients. Prevalence rates for recurrent PBC (rPBC) reported by individual LT programs range between 9% and 35%. The diagnostic hallmark of rPBC is histologic identification of granulomatous changes. Clinical and biochemical features are frequently absent with rPBC and cannot be used alone for diagnostic purposes. Some of the risk factors of rPBC may include recipient factors such as age, gender, HLA status and immunosuppression, as well as donor factors such as age, gender and ischemic time, although controversy exists. Most patients have early stage disease at the time of diagnosis, and there may be a role for therapy with ursodeoxycholic acid. While short- and medium-term outcomes remain favorable, especially if compared to patients transplanted for other indications, continued follow-up may identify reduced long-term graft and patient survival.
Silveira
M G
MG
Miles and Shirley Fitterman Center for Digestive Diseases.
Talwalkar
J A
JA
Miles and Shirley Fitterman Center for Digestive Diseases.|William J. Von Liebig Transplant Center, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN.
Lindor
K D
KD
Miles and Shirley Fitterman Center for Digestive Diseases.
Wiesner
R H
RH
Miles and Shirley Fitterman Center for Digestive Diseases.|William J. Von Liebig Transplant Center, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN.
D000328:Adult; D000367:Age Factors; D000368:Aged; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008105:Liver Cirrhosis, Biliary / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D016031:Liver Transplantation; D008875:Middle Aged; D015995:Prevalence; D012008:Recurrence
D007166:Immunosuppressive Agents